Tumour necrosis factor alpha and mucocutaneous leishmaniasis

Parasitology Today

Volumn 15, Issue 2, 1999, Pages 73-75

  Blackwell, Jenefer M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEISHMANIAL AGENT; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PHOSPHODIESTERASE INHIBITOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENE LOCUS; HUMAN; IMMUNOMODULATION; LEISHMANIA BRAZILIENSIS; MINOR HISTOCOMPATIBILITY COMPLEX; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SKIN LEISHMANIASIS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEISHMANIASIS, CUTANEOUS; POLYMORPHISM, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

LEISHMANIA BRAZILIENSIS; PROTOZOA;

EID: 0033080064     PISSN: 01694758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-4758(98)01355-6     Document Type: Review

References (37)

1. McGuire W.et al. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature. 371:1994;508-511.
2. Cabrera M.et al. Polymorphism in TNF genes associated with mucocutaneous leishmaniasis. J. Exp. Med. 182:1995;1259-1264.
3. Khoo S.H.et al. Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS. 11:1997;423-428.
4. Blackwell J.M.et al. Immunogenetics of leishmanial and mycobacterial infections: the Belem family study. Philos. Trans. R. Soc. London Ser. B. 352:1997;1331-1345.
5. Roy S.et al. TNF promoter polymorphism and susceptibility to lepromatous leprosy. J. Infect. Dis. 176:1997;530-532.
6. Brinkman B.M.et al. Tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br. J. Rheumatol. 36:1997;516-521.
7. Kirk C.W.et al. Tumour necrosis factor microsatellites show association with multiple sclerosis. J. Neurol. Sci. 147:1997;21-25.
8. Moffatt M.F., Cookson W.O. Tumour necrosis factor haplotypes and asthma. Hum. Mol. Genet. 6:1997;551-554.
9. Campbell D.A.et al. Polymorphism at the tumour necrosis factor locus and asthma. Monogr. Allergy. 33:1996;125-137.
10. Wilson A.G.et al. Effects of a polymorphism in the human tumour necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3195-3199.
11. Brinkman B.M.N.et al. Functional consequences of the TNFalpha -308 polymorphism on gene expression. Immunology. 86( 1):1995;75.
12. Castes M.et al. Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. Biol. Res. 26:1993;233-238.
13. Barnes P.F.et al. Local production of tumor necrosis factor and IFN-gamma in tuberculosis pleuritis. J. Immunol. 145:1990;149-154.
14. Sampaio E.P.et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med. 173:1991;699-703.
15. Sampaio E.P.et al. The influence of thalidomide on the clinical and immunologic manifestations of erythema nodosum leprosum. J. Infect. Dis. 168:1993;408-414.
16. Sugita Y.et al. Suppression of tumour necrosis factor-alpha expression in leprosy skin lesions during treatment for leprosy. Br. J. Dermatol. 136:1997;393-397.
17. Green S.J.et al. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-α J. Immunol. 145:1990;4290-4297.
18. r congenic mouse strains. Infect. Immun. 59:1991;3935-3944.
19. Flynn J.L.et al. An essential role for interferon alpha in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:1993;2249-2254.
20. Flynn J.L.et al. An essential role for interferon-gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:1993;2249-2254.
21. Moreira A.L.et al. Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J. Exp. Med. 177:1993;1675-1680.
22. Van Antwerp D.J.et al. Inhibition of TNF-induced apoptosis by NF-κ Trends Cell. Biol. 8:1998;107-111.
23. Stevens R.J. The place of thalidomide in the treatment of inflammatory disease. Lupus. 5:1996;257-258.
24. Stirling D., Sherman M., Strauss S. Thalidomide: a surprising recovery. J. Am. Pharm. Assoc. (Wash.). NS37:1997;306-313.
25. Eigler A.et al. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol. Today. 18:1997;487-492.
26. Kwiatkowski D.et al. Anti-TNF therapy inhibits fever in cerebral malaria. Q. J. Med. 86:1993;91-98.
27. Abraham E.et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb sepsis study group. J. Am. Med. Assoc. 273:1995;934-941.
28. Fekada D.et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. New Engl. J. Med. 335:1996;311-315.
29. Elliott M.J.et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumtoid arthritis. Lancet. 344:1994;1105-1110.
30. Stack W.A.et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 349:1997;521-524.
31. Targan S.R.et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. New Engl. J. Med. 337:1997;1029-1035.
32. Moreland L.W.et al. Treatment of rhemuatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl. J. Med. 337:1997;141-147.
33. Firestein G.S., Zvailer N.J. Anticytokine therapy in rheumatoid arthritis. New Engl. J. Med. 337:1997;195-197.
34. Barral-Netto M.et al. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J. Infect. Dis. 163:1991;853-857.
35. Shaw M.et al. Evidence that genetic susceptibility to Mycobacterium tuberculosis in a Brazilian population is under two-locus oligogenic control: linkage study of the candidate genes NRAMP1 and TNFA. Tuber. Lung Dis. 78:1997;35-45.
36. Blackwell J.M. Structure and function of the natural- resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility. Mol. Med. Today. 2:1996;205-211.
37. Bellamy R.et al. Variation in the NRAMP1 gene is associated with susceptibility to tuberculosis in West Africans. New Engl. J. Med. 338:1998;640-644.